Somerset Pharmaceuticals Report issue

Contributed to NME For profit Phase 4
Founded: Tampa FL United States (1986)
Status: Acquired by Mylan (2008)

Organization Overview

First Clinical Trial
2001
NCT00032929
First Marketed Drug
1989
selegiline (zelapar)
First NDA Approval
1989
selegiline (zelapar)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SOMERSET | SOMERSET THERAPS LLC